Lentiviruses have shown great promise for human gene therapy. However, no optimal strategies are yet available for noninvasive imaging of virus biodistribution and subsequent transduction in vivo. We have developed a dual-imaging strategy based on avidin-biotin system allowing easy exchange of the surface ligand on HIV-derived lentivirus envelope. This was achieved by displaying avidin or streptavidin fused to the transmembrane anchor of vesicular stomatitis virus G protein on gp64-pseudotyped envelopes. Avidin and streptavidin were efficiently incorporated on virus particles, which consequently showed binding to biotin in ELISA. These vectors, conjugated to biotinylated radionuclides and engineered to express a ferritin transgene, enabled for the first-time dual imaging of virus biodistribution and transduction pattern by single-photon emission computed tomography and magnetic resonance imaging after stereotactic injection into rat brain. In addition, vector retargeting to cancer cells overexpressing CD46, epidermal growth factor and transferrin receptors using biotinylated ligands and antibodies was demonstrated in vitro. In conclusion, we have generated novel lentivirus vectors for noninvasive imaging and targeting of lentivirus-mediated gene delivery. This study suggests that these novel vectors could be applicable for the treatment of central nervous system disorders and cancer.
Introduction
Lentiviruses are able to efficiently transduce both dividing and nondividing cells leading to long-term gene expression. 1 This ability has made them especially attractive for gene transfer into differentiated tissues giving rise to numerous clinical trials based on the ex vivo transduction of cells. However, for many applications targeted gene transduction to specific tissues through local or intravenous injection would be the ultimate preferred method of gene delivery. Unfortunately, the specificity of the various vector pseudotypes is not always sufficient for the therapeutic need. Therefore, many attempts have been made to develop targetable vectors based on modification of the virus surface genetically, chemically or by using bispecific targeting molecules. 2 One of the most versatile approaches is offered by the avidin-biotin system, which has been adapted for vector targeting by two ways. First, the vectors can be biotinylated chemically [3] [4] [5] [6] or metabolically [7] [8] [9] [10] while bringing the biotinylated targeting molecule in conjunction with avidin. The second approach consists of displaying avidin on the virus surface. Our group has previously described a baculovirus displaying avidin that could be efficiently targeted in vitro.
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As important as choosing the targeting strategy itself is the use of noninvasive imaging techniques to elucidate the specificity of new targeted vectors. In vivo imaging techniques have the potential to provide critical information about the safety and kinetics of viral administration. Compared to the traditional immunological and histological methods, noninvasive imaging methods can follow virus localization with anatomical accuracy in real time. Current imaging methods in gene therapy can be divided into biodistribution and reporter gene imaging (transduction). Reporter gene imaging visualizes the transgene expression whereas biodistribution demonstrates the vector location throughout the body. Single-photon emission tomography (SPECT) and magnetic resonance imaging (MRI) have been previously utilized to image the biodistribution of herpes simplex viruses 12, 13 and baculoviruses 14, 15 but studies using other viral vectors have not been described. To date, the only imaging modality described for lentiviruses are based on optical transduction imaging of the luciferase reporter gene. 16, 17 In the present work, we created recombinant lentivirus vectors displaying avidin or streptavidin fused to the transmembrane anchor of vesicular stomatitis virus G protein (VSV-G) (VSV-G EctoDomain, VSV-GED) 18 pseudotyped with the baculovirus major envelope glycoprotein gp64. We present data on targeting of these lentivirus vectors to transferrin and epidermal growth factor (EGF) and CD46 receptors overexpressed on tumor cells. Moreover, we demonstrated the utility of (strept)avidin display for noninvasive dual imaging of lentivirus biodistribution and transgene expression in vivo while evaluating for the first time the transduction pattern of gp64-pseudotyped lentivirus vectors in the central nervous system (CNS).
Results

Characterization of (strept)avidin-displaying lentiviruses
We generated gp64-pseudotyped lentivirus vectors displaying avidin or streptavidin fused to the transmembrane anchor of VSV-G (Figure 1a) . The optimal ratio of gp64 to SA/AVD-VSV-GED plasmid was found to be 3:1 and higher amount of SA/AVD-VSV-GED plasmid resulted in decreased titers (data not shown). The viral supernatant was harvested, clarified using a 0.22 mm filter and concentrated by ultracentrifugation (19 500 r.p.m., 2 h 20 min). The incorporation of gp64, streptavidin and avidin into the lentiviral particles was determined by immunoblot analysis from equalized amounts of concentrated virus particles (p24 gag TU per ng) (Figure 1b) . Gp64 was detected with gp64 antibody in all lentivirus preparations, suggesting that codisplay of (strept)avidin fusion proteins did not affect its incorporation. Probing with anti-avidin confirmed the proper incorporation of the 23 kDa AVD-VSV-GED protein on the surface of AVD/GP64 viruses. Similarly, the SA-VSV-GED with molecular weight of 27 kDa was detected in the immunoblots with anti-streptavidin. Recombinant proteins of the same size were recognized by VSV-G antibody against the 15 C-terminal amino acids (497-511) of the VSV-G showing significantly higher incorporation of SA-VSV-GED compared to AVD-VSV-GED.
The efficacy of lentivirus production was further determined by measuring the p24 gag concentration from concentrated virus preparations (Figure 1c) . No significant differences in particle concentrations (p24 gag pg ml À1 ) were detected between the gp64-pseudotyped lentivirus compared to SA/GP64 or AVD/GP64.
To determine if (strept)avidin display had an effect on the transduction efficiency of viruses, we assayed the titers on four cell lines in parallel (HeLa, BT4C, SKOV3, HepG2) (Figure 1c) . Titers of 10 7 -10 8 transducing units per ml (TU per ml) were reached in BT4C, SKOV3 and HepG2 cells whereas 10 6 TU per ml was obtained in HeLa cells. The titers of SA/GP64 or AVD/GP64 lentiviruses were close to the titers of GP64-only viruses, suggesting that simultaneous expression of two different envelope proteins had no major influence on the virus production.
We used ELISA to determine if (strept)avidin fusion proteins displayed on the lentivirus surface were accessible for biotin binding. Lentiviruses were allowed to attach to biotin-coated ELISA plates and the bound virus was detected by gp64 antibody. Results showed that AVD/GP64 and SA/GP64 viruses bound to biotincoated plates in a dose-dependent manner but the extent of binding was 3-6 times higher for SA/GP64 (Figure 1d ). On the basis of these results, we chose SA/GP64 lentivirus for in vivo studies.
Targeting in vitro
To analyze lentivirus targeting in vitro, we tested biotinylated ligands and antibodies selectively targeting receptors expressed at high levels on tumor cells (Figure 2 ). Transferrin receptors mediate iron transport into the cells and are upregulated on rapidly dividing cells such as gliomas. 19 We bound ligand and/or antibody against the transferrin receptor to the rat malignant glioma cells (BT4C) and human glioblastoma cells (D54) followed by lentivirus transduction (Figure 2a ). On rat glioma cells, a 20-30% increase in transduction efficiency was seen with AVD/GP64 when targeted with biotinylated transferrin or transferrin antibody whereas with SA/GP64 an increase of 50-60% was achieved. Targeting the human D54 cells with biotinylated transferrin led to a 20 and 40% increase in the number of green fluorescent protein (GFP)-expressing cells with AVD/GP64 and SA/GP64, respectively. No change in the percentage of GFPexpressing cells was seen with GP64 control virus after treatment of BT4C and D54 cells with the targeting molecules.
Besides transferrin, overexpression of epidermal growth factor receptor (EGFR) is frequently found in several human cancers and is associated with an aggressive tumor behavior. 20 Cancer cell lines with high EGFR expression (SKOV3, HepG2, A549) were targeted with biotinylated EGFR antibody (Cetuximab) whereas the non-biotinylated antibody served as a control ( Figure  2b ). 100% increase in transduction was seen with the SA/ GP64 when targeted with the biotinylated anti-EGFR. Interestingly, the transduction efficiency of AVD/GP64 was only enhanced by 10-40% with the same antibodymediated targeting. The targeting effect was abolished when the non-biotinylated anti-EGFR was used confirming that the unbound antibodies are not responsible for the increased transduction and avidin-biotin bond is mediating virus binding. No significant increase in the transduction was achieved with GP64 vector in all the cell lines studied. To test the cognate ligand of EGFR, we pretreated SKOV3 cells with biotinylated EGF before transduction with the lentivirus vectors. In line with the anti-EGFR results, EGF was able to increase the SA/ GP64 transduction by 50% whereas no significant effect was seen with AVD/GP64 or GP64 vectors.
CD46 has also been shown to be overexpressed on some human neoplasms protecting these cells from destruction by the complement system. 21 A human glioblastoma cell line, U118MG, was chosen to examine the efficacy of CD46 antibody-mediated viral targeting (Figure 2c ). Biotinylated anti-CD46 was shown to increase the transduction efficiency of SA/GP64 by 300% and of AVD/GP64 by 200% compared to untargeted virus and control virus.
In vitro MRI
For noninvasive imaging of virus transduction, we utilized ferritin as endogenous MRI reporter gene. The
Targeting and imaging of (strept)avidin lentivirus MU Kaikkonen et al overexpression of ferritin has been shown to be sufficient to augment the iron uptake of cells giving rise to significant contrast in situ in the absence of exogenously administered MRI substrates. [22] [23] [24] To evaluate the ability of human heavy chain of ferritin (hHF) expressing lentivirus to increase iron uptake in vitro, we measured relaxation rate R2 (R2 ¼ 1/T2) in AVD/GP64-hHF-transduced HepG2 cells 48 h post-transduction (p.t.) ( Figure 3 ). Transduced cells grown in their normal growth medium, having 10% fetal bovine serum as the only iron source, showed little increase in the R2 compared to the control cells. Supplementation of the medium with iron resulted in twofold increase in the R2 compared to the controls. These results confirmed that The data from the same viral dilutions of SA/GP64 and AVD/GP64 were compared pair wise to the GP64 control virus using a two-way ANOVA with Bonferroni's post-test; **Po0.01, ***Po0.001.
Targeting and imaging of (strept)avidin lentivirus MU Kaikkonen et al lentivirus transduction leads to ferritin expression and thus to iron storage inside the cells at levels detectable with MRI.
Imaging virus biodistribution by SPECT/CT in vivo
Virus biodistribution was studied using SPECT/CT by attaching 111
In-labeled biotin-poly-Lys-DTPA on (strept) avidin on the viral surface. Rats were monitored during 3 days after injection of the radiolabeled lentivirus or radiolabeled chelate alone into the right corpus callosum. On the first and third days only planar images were taken. On day 2 both planar and three-dimensional (3D) images were taken ( Figure 4 ). Clear accumulation of the signal was seen in the brain area in all rats up to the third day (Figures 4a-c) . Interestingly, one of the rats injected with radiolabeled virus showed leakage to the circulation during the injection leading to a clear signal in the peritoneal area on day 2 in 3D images (Figure 4e ). No accumulation of indium was seen in the abdomen of the rats with successful injections (Figure 4d ). Three rats injected with 111 In-labeled biotin-poly-Lys-DTPA alone showed signal accumulation to the kidney area on the first day, which shifted to the bladder on day 2 ( Figure  4f ). This is explained by the small molecular size of the chelate (below 10 000 Da) that leads to its transfer to the circulation and subsequent elimination by the kidneys and bladder.
MRI of viral transduction in vivo
To monitor the transgene expression after virus injection to corpus callosum, we performed scans on animals at 4.7 T MRI at days 3, 14, 28, 94, 141 and 211. Using T2*-weighted MRI, we detected the increase in intracellular iron caused by ferritin expression as a negative contrast along the needle track and in the injection site after inoculation of SA/GP64-hHF ( Figure 5a ). Control animals receiving SA/GP64-LacZ lentivirus or 111 In-labeled biotin-poly-Lys-DTPA alone showed minor signal loss at the injection site at day 3 (Figures 5b and c) . This resolved, with one exception, before later measurements and was attributed to small hemorrhage caused by injection. One animal receiving SA/GP64-LacZ, however, showed sustained negative contrast on T2*-weighted sequence up to day 35 that was attributed to extensive chronic hemorrhage as confirmed visually from the histological sections (data not shown).
To verify the source of MRI contrast, we performed histological evaluation of randomly selected animals by Perls' Prussian Blue, anti-ferritin and X-gal stainings 5 or 211 (anti-ferritin only) days after viral inoculation. The results showed ferritin expression and iron accumulation in the cells of the corpus callosum at the site of injection (Figures 6a-d) . Ferritin expression was still detected from transduced tissues at 211 days time point ( Figure  6e ). The X-gal staining pattern of SA/GP64-LacZ transduced rats was also detected along the needle track, 
Discussion
Modification of a lentivirus surface for every new gene therapy application can be laborious and time -consuming, requiring cloning, production and safety evaluation of every new virus. Ideally, one virus platform could be used for many different purposes. To solve this challenge, we developed a novel versatile lentivirus based on avidin-biotin system allowing easy exchange of the ligand on lentivirus envelope. This strategy opens new fields for lentivirus purification, targeting and imaging applications. In this work, the two latter approaches were studied.
Targeting lentiviral entry is one of the major goals in the development of vectors for gene therapy. Selective gene delivery would reduce the potential side effects and ease clinical applications. 2 First method described to alter lentiviral tropism was pseudotyping. 25 The most widely used pseudotyping tool is the VSV-G that stabilizes the otherwise fragile lentivirus and offers a remarkably broad tropism. 26 However, the cytotoxicity of VSV-G limits its use and therefore other alternatives have been sought. [26] [27] [28] The baculovirus major envelope protein gp64 has proven especially attractive as its expression is not cytotoxic and allows the production of vectors with high particle stability. 29 Numerous studies have shown that gp64-pseudotyped HIV and FIV vectors efficiently transduce various cell types in vitro and in vivo. [29] [30] [31] [32] The specificities of viral attachment proteins do not always coincide with those that are required for targeted gene delivery, and incorporation of additional ligands is needed. Ideally, different targeting molecules would be readily coupled to a validated vector and this vectorligand complex would retain its integrity under physiological conditions. The very high affinity (
À15 M) of the binding of streptavidin and avidin to biotin could offer such an approach. Indeed, a recent study by Pereboeva et al. 10 provided evidence of the applicability of this system for the targeting of adenovirus in vivo. To create an efficient and versatile tool for targeting and imaging purposes, we constructed lentiviral vectors pseudotyped with gp64 and displaying avidin and streptavidin. This two-step system is easier to control than the three-step process that relies on the avidin bridge between the biotinylated vector and targeting molecule while offering better valence for coverage because all four biotin-binding sites are available on the lentivirus envelope.
The results from the targeting studies in vitro proved that retargeting to EGFR, CD46 and transferrin receptors increased the transduction of SA/GP64 and in the case of CD46 also that of AVD/GP64, thus providing potential targets for ex vivo and in vivo work. The targeting was able to increase the transduction efficiency up to threefold even though a short virus incubation time (15 min) was used. This effect was more significant with SA/GP64 probably due to its higher incorporation on the viral membranes translating into more efficient biotinbinding capacity. Optimization of virus production might be needed to attain higher avidin levels on AVD/GP64 surface. On the other hand, each avidin monomer has a high isoelectric point (pI) of 10.5 and a single oligosaccharide moiety whereas streptavidin has a mildly acidic pI of B6 and is devoid of sugars. 33 Owing to these dissimilarities, streptavidin has the advantage of lower nonspecific binding to lectin-like and negatively charged molecules than avidin, which might contribute to the differences seen in targeting efficiency. To some extent, the differential biotin-binding efficacy of these vectors might be due to the slight structural deviations between avidin and streptavidin; biotin-binding sites being more accessible on streptavidin. 34 Even though avidin binds free biotin more efficiently, the biotin conjugates have been shown to be more stable with streptavidin than with avidin. 35 In line with previous studies by Morizono et al. 36 and Lin et al.
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, the separation of targeting moiety and fusion protein circumvents the problems resulting from the inability of ligand binding to induce the conformational changes required for fusion and/or sequestration of vectors into endosomes and their subsequent degradation. Consequently, the ligand or antibody binding can induce receptor activation and lead to endocytosis through clathrin-coated pits, which is the one of the possible pathways for gp64-mediated entry. 38, 39 All the receptors retargeted in this study are known to exploit the clathrin-mediated uptake route. 
Targeting and imaging of (strept)avidin lentivirus MU Kaikkonen et al
Pseudotyping of our vectors with gp64 can be an advantage for applications requiring a broad vector tropism, but it can limit the selective targeting of specific cell types if (strept)avidin-binding molecules are not solely responsible for virus binding. To achieve more stringent targeting in vivo, cell-binding-defective envelope protein mutants should be considered as described for hemagglutinin of influenza A, 36 measles virus 40 and Sindbis virus 16, 37, 41 envelope proteins, thus allowing the targeting protein alone direct viral binding. It might also be feasible to create similar mutants of gp64 as the motifs responsible for receptor binding have been elucidated. 42 We are currently investigating the utility of these approaches for targeting of (strept)avidin-displaying viruses in vivo.
Noninvasive imaging would be essential to follow the fate of lentivirus vectors in tissues, to quantify relative injected dose in various organs and to analyze the subsequent transgene expression in the target organs. Imaging of CNS, tumor and cardiovascular tissues could enable evaluation of the most efficient therapeutic approach. Imaging methods can be divided into biodistribution and transduction imaging. Transduction imaging visualizes the transgene expression whereas biodistribution demonstrates the vector location in the body. The virus biodistribution may yield an inaccurate picture of transduction pattern, as a virus may be able to enter into many cells but unable to express its transgenes in all cells. Therefore, it is desirable to obtain images with both imaging modalities to obtain conclusive data on the safety and efficacy of gene therapy.
In our study, noninvasive SPECT and MRI were combined for the first time to simultaneously monitor lentiviral particle distribution and gene expression in rat In-labeled virus at the injection site, indicating that the radiolabeled virus particles remained in the rat brain. We recognize that indirect radiolabeling of the virus might underestimate the particle number in case not all vector particles are labeled thus requiring a second evaluation method to verify the presence of vector particles in tissue. In this respect, we performed a reverse transcriptase (RT)-PCR from the liver and spleen of the animals, confirming that no signal was seen elsewhere in the body. Interestingly, accidental injection of the virus to the circulation in one rat resulted in clear accumulation to the peritoneal area. There was no signal in the liver, kidneys or bladder, suggesting that the virus stayed intact in the circulation and had tropism to the peritoneum. These results provide evidence of the applicability of SPECT imaging in verifying the success of virus administration.
SPECT imaging enables to monitor the success of vector delivery, but it does not provide evidence of the efficiency of gene transfer. Ferritin was chosen as a transgene to study the success of lentiviral gene delivery to the rat brain, as it requires no exogenous contrast agents for detection by MRI. [22] [23] [24] Hemorrhage caused by injection appeared on T2*-weighted gradientecho images of all animals at day 3 but as acute hematoma resolved within a few days, 43 only the specific signal from ferritin was detected. The MRI contrast was seen during the entire 7-month time course investigated, thus confirming stable expression of ferritin in the brain. The transgene expression was detected along the needle track, in the corpus callosum and in the cuboidal epithelial cells of the choroid plexus. Transduction of the choroid plexus cells and corpus callosum suggests that gp64-pseudotyped lentiviruses exhibit somewhat similar tropism to baculoviruses. 44, 45 Altogether, these results indicate that gp64-pseudotyped lentivirus vectors may provide an efficient tool for gene therapy of CNS disorders. Furthermore, the technology presented here can be adapted to monitor the therapeutic gene delivery to other tissues. By coexpression of a therapeutic gene with ferritin from a dual expression cassette, the ferritin expression can be linked with treatment efficacy.
In conclusion, this work gives proof of principle of the utility of (strept)avidin display as a versatile tool for targeting of lentivirus vectors. This conjugatebased strategy is readily adaptable for different targets to increase the gene delivery for ex vivo applications. In this study, we also extended the use of (strept)avidin display to image lentivirus biodistribution and using human ferritin as a marker to follow the duration of transgene expression. These new vectors could be used for designing new gene therapy strategies for a variety of diseases, such as CNS disorders and cancer.
Materials and methods
Construction of plasmids for lentiviruses production
Envelope plasmids encoding gp64 or (strept)avidin fused to membrane anchor of VSV-G were constructed by removing VSV-G from plasmid pCMV-VSV-G and replacing it with a linker (5 0 -AATTCCCTAGGATTTAA ATGCTAGCGTTTAAACGATATCG-3 0 and 5 0 -AATTCG ATATCGTTTAAACGCTAGCATTTAAATCCTAGGG-3 0 ). Gp64 was cut from pBACsurf-1 (Novagen, Darmstadt, Germany) with SnaBI and SpeI and cloned to the linker digested with PmeI and AvrII (New England Biolabs Inc., Ipswich, MA, USA). Construction of avidin-and streptavidin-displaying vectors began by the removal of gp64 gene from the Baavi vector. 11 The VSV-G TM/CTD (VSV-GED) 18 domain was amplified by PCR using the following primers: forward 5 0 -GGGGTGATACTGGGCTATCC AA-3 0 , reverse 5 0 -AGATCTTTACTTTCCAAGTCGGT TCA-3 0 and ligated to SmaI (New England Biolabs Inc.) digested vector giving rise to AVD-VSV-GED baculovirus vector. Tetrameric avidin was replaced with streptavidin sequence resulting in SA-VSV-GED vector. AVD-VSV-GED and SA-VSV-GED were digested from these vectors with SnaBI and SpeI enzymes and cloned to pCMV-linker vector digested with PmeI and AvrII.
hHF gene (pENTR 221-Ferritin; RZPD German Resource Center for Genome Research, Berlin, Germany) and LacZ 11 were cloned to the third-generation lentivirus transfer plasmid pBOB-CAG under CAG (chicken betaactin promoter with CMV-IE enhancer) promoter, using Figure 5 Longitudinal results of T2*-weighted gradient echo magnetic resonance images in vivo. Rat brain was imaged 3-211 days after injection of (a) 111 In-labeled SA/GP64-hHF lentivirus, (b) SA/GP64-LacZ or (c) 111 In-labeled multi-Lys-DTPA chelate alone. Lentivirus injection led to signal void area (arrows), corresponding to ferritin expression and subsequent accumulation of iron. Injection of the SA/GP64-LacZ and chelate alone resulted in minor loss of signal at day 3 (arrows) along the needle track caused by bleeding that was no longer detectable at later time points.
Targeting and imaging of (strept)avidin lentivirus MU Kaikkonen et al gateway technology (Invitrogen, Carlsbad, CA, USA). All constructs were verified by sequencing.
Preparation and titering of lentivirus vectors
Third-generation self-inactivating lentiviruses were prepared by four or five plasmid transient transfection in 293T cells as described. 46 The amounts of pMDLg/ pRRE, pRSV-Rev, pGp64 and transfer plasmid per 15 cm dish were 12.5, 6.25, 13.0 and 25.0 mg, respectively. The transfer plasmids were pBOB-CAG-hHF, pBOB-CAG-LacZ and LV1-GFP. 47 The amount of AVD-VSV-GED or SA-VSV-GED was optimized using a range of 1-9 mg. The virus containing supernatant was harvested, clarified using a 0.22 mm filter and concentrated by ultracentrifugation (1 95 000 r.p.m., 2 h and 20 min). Targeting and imaging of (strept)avidin lentivirus MU Kaikkonen et al Transforming units of lentiviruses (TU per ml) were determined by analyzing the number of virus particles able to transduce cells. BT4C, 48 HeLa, HepG2 or SKOV3 (ATCC) cells were seeded in 96-well plates at 5000 cells per well. The lentivirus transduction was carried out next day with serial dilutions (1:1000-1:10 00 000) of the concentrated virus preparation. After 3 days, the cells were analyzed by flow cytometry (FACSCanto II; BD Biosciences, San Diego, CA, USA) to reveal the percentage of the GFP-positive cells. Titers were calculated as described previously. 46 The amount of lentiviral capsid protein p24 (pg ml
À1
) was determined by p24 ELISA kit (PerkinElmer, Waltham, MA, USA).
Immunoblotting
The display of gp64, streptavidin-VSV-GED and avidin-VSV-GED on the lentivirus surface was detected by using mouse anti-gp64 (eBioscience, San Diego, CA, USA), rabbit anti-avidin, anti-streptavidin and anti-VSV-G (Bethyl Laboratories, Montgomery, TX, USA) antibodies. Primary antibodies were detected with secondary alkaline-phosphatase-conjugated goat anti-mouse or antirabbit antibodies (Bio-Rad, Hercules, CA, USA) followed by a color reaction (NBT/BCIP; Roche, Basel, Switzerland). Bound virus was detected with mouse anti-gp64 antibody (eBioscience) followed by horseradish peroxidase (HRP)-conjugated anti-mouse antibody (Silenus Laboratories, Hawthorn, Australia). Finally, the plates were washed and substrate (0.5% TMB diluted 1:50 in 0.1 M NaAc, 1.5 mM citric acid, 0.005% 30% H 2 O 2 ) was added. Color development was stopped with 2 M H 2 SO 4 and absorbances were measured at 450 nm.
Targeting in vitro
Cells were seeded at 10 000 cells per 96-well plate in their recommended medium. After 24 h medium was removed and cells were washed twice with cold 1% BSA-PBS (phosphate-buffered saline) and placed on ice for 5 min. Targeting molecules were as follows: biotinylated transferrin (5 mg ml 
Stereotactic injections into rat brain
Male inbred Wistar rats (200-250 g) were anesthetized intraperitoneally with a solution containing ketamine (Ketalar; Pfizer Oy Animal Health, Espoo, Finland) and medetomidine (Domitor; Orion Pharma, Espoo, Finland) and placed into stereotactic apparatus (Kopf Instruments, Tujunga, CA, USA). For SPECT/CT, a total volume of 15 ml of the 111 In-labeled solution was injected into the right corpus callosum (coordinates: 1.0 mm caudal to bregma, 1.5 mm right to sutura sagittalis and depth of 3.0-3.5 mm) using a Hamilton syringe with a 27-gauge needle. Control rats (n ¼ 3) received chelate only whereas virus-injected animals received SA/GP64-hHF (n ¼ 15) or SA/GP64-LacZ lentivirus (n ¼ 7).
In vitro and in vivo MRI
To confirm the iron uptake of ferritin-expressing lentivirus, we measured R2 relaxation times from the lentivirus-transduced (MOI 10) HepG2 cells incubated in medium with or without 2 mM ferric ammonium citrate supplement (Sigma-Aldrich) 48 h p.t. Samples were imaged using 4.7 T MRI system (Magnex, Abington, UK) interfaced to Varian Unity INOVA console (Varian Inc., Palo Alto, CA, USA). Standard spin-echo pulse sequence with time to repetition (TR) of 2 s and time to echo (TE) of 15, 35 and 55 ms was used to obtain data for T2 maps. In the measurements slice thickness was 1.5 mm, field of view (FOV) of 50 Â 50 mm was covered with 256 Â 128 points. Quantitative relaxation rate maps were computed using standard two-parameter fit and central region of the pellet was chosen for the region-of-interest (ROI) analysis of R2 value.
The experimental animals underwent MRI 3, 14, 28, 52, 63, 94, 141 and 211 days after the stereotactic injection. For imaging, animals were anesthetized with 1% halothane in 74%:25% N 2 O/O 2 . MRI was performed using the 4.7 T magnet. Animals were imaged by T2*-weighted gradient-echo sequence (TR/TE ¼ 1.5 s/ 0.015 s. The parameters for T2* scans were TR/TE ¼ 1.5 s/0.015 s. Total of 11 slices were imaged from each brain with a slice thickness of 1 mm, gap between the slices being 0.8 mm. FOV of 4 Â 4 cm was covered with 256 Â 128 points. Image reconstruction and analyses were performed using MatLab 7.1. (The MathWorks Inc., Natick, MA, USA).
In vivo SPECT/CT imaging
Biotinylated multi-Lys-DTPA conjugate was synthesized as described 15 and labeled with 111 indium chloride (Mallinckrodt Medical, Petten, Holland). After incubation the radiochemical purity of the multi-Lys-DTPA was checked using instant thin-layer chromatography (SG; Pall Corporation, OEM Healthcare, Ann Arbor, MI, USA). Virus was added to the labeled multi-Lys-DTPA solution and a total volume of 15ml having an activity B2 MBq was injected. In chelate controls, the virus volume was replaced with labeling buffer. The injections were given as described above.
All animals were imaged during 3-day period. The animals were anesthetized using 1.5-2.0% isoflurane in In was used. 3D imaging was performed using 64 projections and 60 s per projection. Matrix size was 80 Â 80 in 125 Â 125 m FOV. CT imaging was performed using the same coordinates as SPECT with 512 projections, 1024 Â 1024 projection matrix size and a voltage of 70 kV. The planar SPECT images were combined to X-ray image with Matlab 7.1. (The MathWorks Inc.). 3D SPECT reconstruction was carried out by LumGem program (Gamma Medica) using Butterworth six-order low-pass postfiltering with cutoff frequency of 0.3. 3D images with dimensions of 512 Â 512 Â 512 matrix size in 87 Â 87 Â 87 mm FOV were obtained. Both CT and SPECT images were interpolated into final 256 Â 256 Â 256 size by using vendor software (Gamma Medica). The images are combined using IDL software (ITT Visual Information Solutions, Washington, VA, USA) and monitored with Amira software (Mercury, Carlsbad, CA, USA).
Histology and immunohistochemistry
Randomly selected rats were killed and perfused with PBS intracardially 5, 28 and 211 days after injection. Brains were removed and frozen within Tissue-Tek OCT Compound (Electron Microscopy Sciences, Forth Washington, PA, USA) and cryosections of 12 mm were cut. Samples from liver, spleen, kidney, hearth, lung and muscle were collected and frozen in liquid nitrogen for mRNA analysis.
Ferritin expression was detected using a modified Perl's Prussian Blue staining and antibody against hHF rHO2. 49 In the Perl's Prussian Blue staining, the tissues sections were incubated in a solution of 7% ferrocyanide and 3% hydrochloric acid (Sigma-Aldrich) and subsequently in DAB solution (Zymed Laboratories Inc., San Francisco, CA, USA). For antibody stainings, the primary antibody rHO2 was probed with an HRPconjugated mouse antibody (Vectastain ABC Kit; Vector Labs, Burlingame, CA, USA). Sections were counterstained in Harris hematoxylin (Merck KGaA) and mounted with Permount (Fisher Chemicals, Fair Lawn, NJ, USA). The LacZ expression of was analyzed as described. 46 
Quantitative RT-PCR
The tissue samples were dissolved in TRI Reagent (Sigma-Aldrich). Total RNA was isolated by phenolchloroform extraction, treated with DNaseI (Promega, Madison, WI, USA) and reverse transcribed. Similar treatment was carried out for HepG2 cells to obtain a positive control for human ferritin transcription. SYBR Green (Applied Biosystems, Foster City, CA, USA) RT-PCR was used to quantify the amount of human and rat ferritin mRNA using specific primers: forward for human and rat ferritin 5 0 -GGAACATGCTGAGA AACTGATGAAG, reverse for human ferritin 5 0 -CACA GTCTGGTTTCTTGATATCCTGA and reverse for rat ferritin 5 0 -CACGGTCAGGTTTCTTTATATCCTGC. Samples were amplified using ABI PRISM 7700 Sequence Detection System (Applied Biosystems) under the following conditions: 2 min at 50 1C, 10 min at 95 1C, followed by 40 cycles of 15 s at 95 1C and 1 min at 60 1C. Input amounts of cDNAs were corrected by amplification of the 18S ribosomal RNA as an endogenous control using TaqMan Ribosomal RNA Control Reagents (Applied Biosystems).
Statistical analyses
Statistical analyses were performed by GraphPadPrism 5 (GraphPad Software Inc., San Diego, CA, USA).
